Sartorius/€SRT3
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About Sartorius
Sartorius AG, trading under the ticker symbol SRT3, is a global provider of laboratory and bioprocess technologies, offering products and services that cater to the needs of the biopharmaceutical and research industries. Founded in 1870 and headquartered in Göttingen, Germany, the company specializes in filtration, fermentation, fluid management, and laboratory products, supporting clients ranging from research facilities to large-scale biopharmaceutical manufacturers. Operating internationally, Sartorius is crucial in enabling the development and production of biotech medications and vaccines, solidifying its role as a crucial player in the life sciences and biotechnology sectors.
Ticker
€SRT3
Sector
Primary listing
XETRA
Industry
Life Sciences Tools & Services
Headquarters
Employees
13,573
ISIN
DE0007165631
Website
Sartorius Metrics
BasicAdvanced
€14B
-
-
1.24
€0.74
0.34%
Price and volume
Market cap
€14B
Beta
1.24
52-week high
€292.00
52-week low
€166.05
Average daily volume
136K
Dividend rate
€0.74
Financial strength
Current ratio
1.458
Quick ratio
0.822
Long term debt to equity
109.459
Total debt to equity
120.637
Dividend payout ratio (TTM)
53.03%
Interest coverage (TTM)
2.15%
Profitability
EBITDA (TTM)
753.3
Gross margin (TTM)
45.27%
Net profit margin (TTM)
2.78%
Operating margin (TTM)
13.05%
Effective tax rate (TTM)
26.50%
Revenue per employee (TTM)
€250,000
Management effectiveness
Return on assets (TTM)
2.71%
Return on equity (TTM)
4.12%
Valuation
Dividend yield (TTM)
0.34%
Forward dividend yield
0.34%
Growth
Revenue change (TTM)
3.99%
3-year revenue growth (CAGR)
-2.21%
10-year revenue growth (CAGR)
13.79%
3-year dividend per share growth (CAGR)
-16.26%
10-year dividend per share growth (CAGR)
10.82%
What the Analysts think about Sartorius
Analyst ratings (Buy, Hold, Sell) for Sartorius stock.
Bulls say / Bears say
Sartorius reported a 6.71% year-over-year increase in revenue for Q4 2024, indicating strong financial performance. (Google Finance)
The company's net operating cash flow tripled to €139 million in Q1 2025, showcasing improved financial health. (Seeking Alpha)
Analysts forecast earnings to grow by 28.44% per year, suggesting strong future growth potential. (Simply Wall St)
Sartorius has a high level of debt, which could pose financial risks. (Simply Wall St)
Profit margins have decreased from 4.5% to 2.8% year-over-year, indicating potential profitability concerns. (Simply Wall St)
The stock is trading at a high P/E ratio of 156.22, suggesting it may be overvalued. (Google Finance)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
Sartorius Financial Performance
Revenues and expenses
Sartorius Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sartorius stock?
Sartorius (SRT3) has a market cap of €14B as of July 01, 2025.
What is the P/E ratio for Sartorius stock?
The price to earnings (P/E) ratio for Sartorius (SRT3) stock is 0 as of July 01, 2025.
Does Sartorius stock pay dividends?
Yes, the Sartorius (SRT3) stock pays dividends to shareholders. As of July 01, 2025, the dividend rate is €0.74 and the yield is 0.34%. Sartorius has a payout ratio of 53.03% on a trailing twelve-month basis.
When is the next Sartorius dividend payment date?
The next Sartorius (SRT3) dividend payment date is unconfirmed.
What is the beta indicator for Sartorius?
Sartorius (SRT3) has a beta rating of 1.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.